News Pfizer Pharma

Pfizer’s JAK Inhibitor Abrocitinib Hits its Primary Endpoint in a Second Phase 3 Trial for Atopic Dermatitis

Biotech News | 27.09.2019

Pfizer’s drug Abrocitinib, an oral inhibitor of the Janus kinase 1 (JAK1), met its primary...